These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26447989)

  • 1. Performance of bioresorbable vascular scaffolds versus cobalt-chromium everolimus-eluting stent in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: a review of currently available clinical data.
    Buccheri D; Piraino D; Chirco PR; Cortese B
    Minerva Cardioangiol; 2016 Feb; 64(1):74-83. PubMed ID: 26447989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study.
    Fam JM; Felix C; van Geuns RJ; Onuma Y; Van Mieghem NM; Karanasos A; van der Sijde J; De Paolis M; Regar E; Valgimigli M; Daemen J; de Jaegere P; Zijlstra F; Diletti R
    EuroIntervention; 2016 May; 12(1):30-7. PubMed ID: 27173859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of everolimus eluting bioabsorbable vascular scaffold (BVS) compared to non BVS drug eluting stent in the management of ST-segment elevation myocardial infarction (STEMI) - A comparative study.
    Chakraborty R; Patra S; Banerjee S; Pande A; Khan A; Mandol PC; Ghosh D; De SK; Das SS; Nag R
    Cardiovasc Revasc Med; 2016; 17(3):151-4. PubMed ID: 26905052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions.
    Cortese B; Ielasi A; Romagnoli E; Varricchio A; Cuculo A; Loi B; Pisano F; Corrado D; Sesana M; La Vecchia L; Summaria F; Tespili M; Silva Orrego P; Tognoni G; Steffenino G
    Am J Cardiol; 2015 Sep; 116(5):705-10. PubMed ID: 26100584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study.
    Räber L; Onuma Y; Brugaletta S; Garcia-Garcia HM; Backx B; Iñiguez A; Okkels Jensen L; Cequier-Fillat À; Pilgrim T; Christiansen EH; Hofma SH; Suttorp M; Serruys PW; Sabaté M; Windecker S
    EuroIntervention; 2016 Jul; 12(4):482-9. PubMed ID: 26342471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
    Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
    JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents.
    Sorrentino S; Giustino G; Mehran R; Kini AS; Sharma SK; Faggioni M; Farhan S; Vogel B; Indolfi C; Dangas GD
    J Am Coll Cardiol; 2017 Jun; 69(25):3055-3066. PubMed ID: 28412389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction.
    de Hemptinne Q; Picard F; Ly HQ; Ibrahim R; Asgar AW; de Guise P; Doucet S; Dorval JF; Marquis-Gravel G; Levi M; L-L'allier P; Tanguay JF
    Acta Cardiol; 2018 Jun; 73(3):276-281. PubMed ID: 28954592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-inflammatory response after bioresorbable vascular scaffold implantation in patients with acute myocardial infarction with ST elevation in a long-term perspective.
    Kozel M; Kočka V; Lisa L; Buděšínský T; Toušek P
    Heart Vessels; 2019 Apr; 34(4):557-563. PubMed ID: 30315494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
    Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes with bioabsorbable vascular scaffolds versus everolimus eluting stents: Insights from randomized trials.
    Bangalore S; Toklu B; Bhatt DL
    Int J Cardiol; 2016 Jun; 212():214-22. PubMed ID: 27045877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
    Lee HJ; Park TK; Song YB; Choi YJ; Yu CW; Yang JH; Hahn JY; Choi SH; Choi RK; Choi JH; Park JS; Kim JS; Kim TH; Jang HJ; Lee SH; Shim WH; Roh YM; Gwon HC
    Int J Cardiol; 2015 Mar; 183():190-7. PubMed ID: 25668147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison.
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Ortega-Paz L; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Giacchi G; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    Int J Cardiol; 2016 Jul; 214():483-4. PubMed ID: 27096965
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality difference of neointima following the implantation of everolimus-eluting bioresorbable scaffolds and metallic stents in patients with ST-elevation myocardial infarction: quantitative assessments by light intensity, light attenuation, and backscatter on optical coherence tomography in the TROFI II trial.
    Sotomi Y; Onuma Y; Liu S; Asano T; Eggermont J; Katagiri Y; Cavalcante R; de Winter RJ; Wykrzykowska JJ; Brugaletta S; Räber L; Sabaté M; Windecker S; Dijkstra J; Serruys PW
    EuroIntervention; 2018 Aug; 14(6):678-685. PubMed ID: 29488886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients With Chronic Total Coronary Occlusions: Acute Procedural and Short-Term Clinical Results.
    Goktekin O; Yamac AH; Latib A; Tastan A; Panoulas VF; Sato K; Erdogan E; Uyarel H; Shah I; Colombo A
    J Invasive Cardiol; 2015 Oct; 27(10):461-6. PubMed ID: 26429848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
    Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
    JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use.
    Sotomi Y; Suwannasom P; Tenekecioglu E; Tateishi H; Abdelghani M; Serruys PW; Onuma Y
    Expert Rev Cardiovasc Ther; 2015 Oct; 13(10):1127-45. PubMed ID: 26401921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.